Senseonics (NYSE:SENS) Stock Price Up 8.4% - Here's What Happened

Shares of Senseonics Holdings, Inc. (NYSE:SENS - Get Free Report) were up 8.4% during trading on Friday . The stock traded as high as $1.12 and last traded at $1.10. Approximately 4,920,939 shares traded hands during trading, a decline of 78% from the average daily volume of 22,190,742 shares. The stock had previously closed at $1.01.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. StockNews.com initiated coverage on shares of Senseonics in a research note on Thursday, December 26th. They set a "sell" rating for the company. HC Wainwright reissued a "buy" rating and set a $2.00 price target on shares of Senseonics in a research report on Friday, November 15th.

Senseonics Trading Up 11.9 %

The firm's 50 day simple moving average is $0.50 and its 200-day simple moving average is $0.42. The company has a market capitalization of $672.72 million, a PE ratio of -8.69 and a beta of 0.64. The company has a quick ratio of 2.38, a current ratio of 2.47 and a debt-to-equity ratio of 59.17.

Senseonics (NYSE:SENS - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.01). The business had revenue of $4.26 million for the quarter, compared to analysts' expectations of $4.02 million. Senseonics had a negative return on equity of 842.25% and a negative net margin of 362.30%. As a group, equities research analysts anticipate that Senseonics Holdings, Inc. will post -0.14 EPS for the current year.

Remove Ads

Insiders Place Their Bets

In related news, CFO Frederick T. Sullivan purchased 124,933 shares of the business's stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average cost of $0.38 per share, with a total value of $47,474.54. Following the completion of the acquisition, the chief financial officer now directly owns 2,478,844 shares of the company's stock, valued at approximately $941,960.72. The trade was a 5.31 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Timothy T. Goodnow acquired 315,000 shares of the firm's stock in a transaction on Tuesday, December 10th. The shares were bought at an average cost of $0.31 per share, with a total value of $97,650.00. Following the completion of the acquisition, the chief executive officer now owns 11,310,355 shares in the company, valued at $3,506,210.05. This represents a 2.86 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Senseonics

Several large investors have recently modified their holdings of the stock. FMR LLC raised its holdings in shares of Senseonics by 48,267.2% during the third quarter. FMR LLC now owns 168,318 shares of the company's stock worth $59,000 after purchasing an additional 167,970 shares during the period. Geode Capital Management LLC grew its position in shares of Senseonics by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company's stock valued at $2,042,000 after buying an additional 179,103 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in Senseonics during the third quarter worth about $117,000. Cubist Systematic Strategies LLC lifted its holdings in Senseonics by 25.9% in the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company's stock worth $166,000 after acquiring an additional 85,501 shares during the last quarter. Finally, Ridgecrest Wealth Partners LLC acquired a new position in Senseonics in the fourth quarter valued at approximately $60,000. Institutional investors own 12.36% of the company's stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.